Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.300
-0.080 (-2.37%)
Nov 18, 2026, 10:41 AM EST - Market open
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.82. The average 1-year stock price forecast is 197.52% higher than the current stock price, while the lowest is $3.00 (-9.09%) and the highest is $16 (+384.85%).
Price Target: $9.82 (+197.52%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 10 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +263.64% | Nov 17, 2026 |
| Wedbush | Wedbush | Hold Downgrades $8 → $3 | Hold | Downgrades | $8 → $3 | -9.09% | Nov 17, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Reiterates $4 | Hold | Reiterates | $4 | +21.21% | Nov 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +384.85% | Nov 16, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +203.03% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
6.50M
from 7.83M
Decreased by -16.95%
Revenue Next Year
5.12M
from 6.50M
Decreased by -21.18%
EPS This Year
-0.58
from -0.53
EPS Next Year
-0.69
from -0.58
EPS and Forward PE are based on non-GAAP adjusted numbers.